The United Kingdom had become the first country to authorize a bivalent vaccine developed by the Moderna laboratory and also targeting Omicron, the most widespread variant in Europe.
Britain's medicines regulator announced on Saturday that it has approved a new generation of Pfizer/BioNTech's COVID-19 vaccine targeting the Omicron variant.
This version of the vaccine consists of a dose of so-called bivalent booster, targeting half the original strain of the virus and half the Omicron (BA.1) variant, the Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement.
It has been approved for booster doses for adults by the MHRA which concluded that it meets the safety, quality and efficacy standards of the British regulator, said the medicine agency, which specifies authorizing the vaccine. for people aged 12 and over.
In mid-August, the United Kingdom became the first country to authorize a similar vaccine developed by the Moderna laboratory and also targeting Omicron, a variant the most widespread in Europe.
The announcement comes as the country prepares to offer a booster dose of the COVID-19 vaccine from Monday to millions of Britons in England and Scotland, including those over the age of 50. years with a priority for people living in nursing homes.
I am pleased to announce that we now have a second vaccine approved for this fall's booster program, s& #x27;is delighted the director of the MHRA, June Raine.
The new vaccines Pfizer and Moderna have been authorized in recent days by the United States and the European Agency of the drug. They are also targeting two rapidly spreading subvariants of the Omicron strain, BA.4 and BA.5
The UK is one of the worst affected countries in Europe by the pandemic, with nearly 180,000 deaths since the start of 2020. While mortality has fallen sharply thanks to vaccination, the country regularly experiences large waves of contamination, but was one of the first in Europe to lift all restrictions last winter.